Nanjing Well Pharmaceutical Co Ltd - Asset Resilience Ratio

Latest as of September 2025: 0.12%

Nanjing Well Pharmaceutical Co Ltd (603351) has an Asset Resilience Ratio of 0.12% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check Nanjing Well Pharmaceutical Co Ltd (603351) strategic asset index to assess the company's strategic physical and investment asset allocation.

Liquid Assets

CN¥3.00 Million
≈ $438.99K USD Cash + Short-term Investments

Total Assets

CN¥2.59 Billion
≈ $378.33 Million USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2019–2023)

This chart shows how Nanjing Well Pharmaceutical Co Ltd's Asset Resilience Ratio has changed over time. See 603351 net asset quality index to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down Nanjing Well Pharmaceutical Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 603351 market cap overview.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents CN¥0.00 0%
Short-term Investments CN¥3.00 Million 0.12%
Total Liquid Assets CN¥3.00 Million 0.12%

Asset Resilience Insights

  • Limited Liquidity: Nanjing Well Pharmaceutical Co Ltd maintains only 0.12% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Nanjing Well Pharmaceutical Co Ltd Industry Peers by Asset Resilience Ratio

Compare Nanjing Well Pharmaceutical Co Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Tonghua Dongbao Pharmaceutical Co Ltd
SHG:600867
Drug Manufacturers - Specialty & Generic 0.76%
Eris Lifesciences Limited
NSE:ERIS
Drug Manufacturers - Specialty & Generic 0.58%
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267
Drug Manufacturers - Specialty & Generic 0.01%
Lotus Pharmaceutical Co Ltd
TW:1795
Drug Manufacturers - Specialty & Generic 0.49%
Tasly Pharmaceutical Group Co Ltd
SHG:600535
Drug Manufacturers - Specialty & Generic 11.69%
Changzhou Qianhong Biopharma Co Ltd
SHE:002550
Drug Manufacturers - Specialty & Generic 18.70%
Renhe Pharmacy Co Ltd
SHE:000650
Drug Manufacturers - Specialty & Generic 37.54%
Sun Pharma Advanced Research Company Limited
NSE:SPARC
Drug Manufacturers - Specialty & Generic 0.64%

Annual Asset Resilience Ratio for Nanjing Well Pharmaceutical Co Ltd (2019–2023)

The table below shows the annual Asset Resilience Ratio data for Nanjing Well Pharmaceutical Co Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2023-12-31 0.05% CN¥1.25 Million
≈ $183.19K
CN¥2.28 Billion
≈ $333.48 Million
+0.00pp
2022-12-31 0.05% CN¥1.11 Million
≈ $161.86K
CN¥2.14 Billion
≈ $312.88 Million
-1.37pp
2021-12-31 1.42% CN¥26.24 Million
≈ $3.84 Million
CN¥1.84 Billion
≈ $269.46 Million
-10.60pp
2020-12-31 12.02% CN¥196.71 Million
≈ $28.78 Million
CN¥1.64 Billion
≈ $239.46 Million
+5.83pp
2019-12-31 6.19% CN¥90.31 Million
≈ $13.22 Million
CN¥1.46 Billion
≈ $213.39 Million
--
pp = percentage points

About Nanjing Well Pharmaceutical Co Ltd

SHG:603351 China Drug Manufacturers - Specialty & Generic
Market Cap
$489.53 Million
CN¥3.35 Billion CNY
Market Cap Rank
#12492 Global
#3682 in China
Share Price
CN¥24.70
Change (1 day)
+1.02%
52-Week Range
CN¥23.50 - CN¥32.52
All Time High
CN¥40.56
About

Nanjing Well Pharmaceutical Group Co.,Ltd. focuses on the research and development, production, and sale of pharmaceutical excipients and synthetic lubricating base oils to the pharmaceutical companies in China. It is involved in the bio-based material manufacturing, sales, and technology development; technical development and consulting; bio-based material technology research and development; bi… Read more